| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 5, 2006
Accepted on October 31, 2007
Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia
* To whom correspondence should be addressed. E-mail: Hugh.Barrett{at}uwa.edu.au.
Context: Apolipoprotein(apo) C-III is associated with hypertriglyceridemia and progression of cardiovascular disease. Plasma apoC-III is elevated in centrally obese men, and we hypothesized that the kinetics of apoC-III are disturbed in these subjects.
Objective: We developed a compartmental model to determine very-low-density lipoprotein (VLDL) and high-density lipoprotein(HDL) apoC-III metabolic parameters in centrally obese men, and investigated the associations with VLDL-apoB and HDL-apoA-I kinetics.
Study Design: Apolipoprotein kinetics was determined using stable isotope techniques and compartmental modelling in 39 centrally obese and 12 non obese men.
Results:Compared with non obese subjects, centrally obese subjects had increased plasma apoC-III concentration (160±5mg/L vs 103±9mg/L, P<0.001), reflecting increased concentrations of both VLDL-apoC-III and HDL-apoC-III. These related to increased production rate (PR) of VLDL-apoC-III (2.12±0.14mg/kg/day vs 1.56±0.29mg/kg/day, P<0.05) and reduced fractional catabolic rate (FCR) of both VLDL- and HDL-apoC-III (0.70±0.02pools/day vs 0.82±0.05pools/day, P<0.05). In centrally obese men, VLDL-apoC-III concentration was significantly (P<0.05) associated with VLDL-apoB concentration and PR, as well as with HDL-apoA-I FCR and PR, and inversely with VLDL-apoB FCR. HDL-apoC-III concentration was significantly (P<0.05) associated with the concentrations of both VLDL-apoB and HDL-apoA-I, the FCR and PR of HDL-apoA-I, and inversely with the VLDL-apoB FCR. In multiple regression analysis, both VLDL-apoC-III and HDL-apoC-III concentrations were significantly associated with HDL-apoA-I FCR.
Conclusions: In centrally obese men, elevated VLDL-apoC-III and HDL-apoC-III concentrations are a consequence of elevated production and decreased catabolism of VLDL-apoC-III and reduced catabolism of HDL-apoC-III, respectively. These defects are associated with disturbances in VLDL-apoB and HDL-apoA-I metabolism.
This article has been cited by other articles:
 |
|
 |
|
  H. N. Ginsberg and R. Ramakrishnan Kinetic Studies of the Metabolism of Rapidly Exchangeable Apolipoproteins May Leave Investigators and Readers With Exchangeable Results Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1685 - 1686. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Chan, G. F. Watts, E. M.M. Ooi, J. Ji, A. G. Johnson, and P. H. R. Barrett Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1831 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pavlic, R. Valero, H. Duez, C. Xiao, L. Szeto, B. W. Patterson, and G. F. Lewis Triglyceride-Rich Lipoprotein-Associated Apolipoprotein C-III Production Is Stimulated by Plasma Free Fatty Acids in Humans Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1660 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M.M. Ooi, G. F. Watts, D. C. Chan, M. M. Chen, P. J. Nestel, D. Sviridov, and P. H. R. Barrett Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome Diabetes Care, August 1, 2008; 31(8): 1656 - 1661. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
